vs

Side-by-side financial comparison of REED'S, INC. (REED) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $7.5M, roughly 1.7× REED'S, INC.). REED'S, INC. runs the higher net margin — -50.5% vs -1398.3%, a 1347.8% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs -23.1%). REED'S, INC. produced more free cash flow last quarter ($-3.9M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs -11.7%).

Waddell & Reed Financial, Inc. was an American asset management and financial planning company founded in 1937 in Kansas City, Missouri. It was a publicly traded company from 1998 to 2021, and briefly had its headquarters in Overland Park, Kansas, and was planning a move back to Downtown Kansas City before the company was sold. It operated asset management and distribution subsidiaries, including Ivy Investment Management Company and Waddell & Reed Investment Management Company.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

REED vs RNA — Head-to-Head

Bigger by revenue
RNA
RNA
1.7× larger
RNA
$12.5M
$7.5M
REED
Growing faster (revenue YoY)
RNA
RNA
+457.2% gap
RNA
434.0%
-23.1%
REED
Higher net margin
REED
REED
1347.8% more per $
REED
-50.5%
-1398.3%
RNA
More free cash flow
REED
REED
$153.0M more FCF
REED
$-3.9M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
-11.7%
REED

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
REED
REED
RNA
RNA
Revenue
$7.5M
$12.5M
Net Profit
$-3.8M
$-174.4M
Gross Margin
20.4%
Operating Margin
-46.9%
-1513.5%
Net Margin
-50.5%
-1398.3%
Revenue YoY
-23.1%
434.0%
Net Profit YoY
8.2%
-117.0%
EPS (diluted)
$-1.26
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
REED
REED
RNA
RNA
Q4 25
$7.5M
Q3 25
$7.0M
$12.5M
Q2 25
$9.5M
$3.8M
Q1 25
$10.0M
$1.6M
Q4 24
$9.7M
$3.0M
Q3 24
$6.8M
$2.3M
Q2 24
$11.9M
$2.0M
Q1 24
$9.6M
$3.5M
Net Profit
REED
REED
RNA
RNA
Q4 25
$-3.8M
Q3 25
$-4.0M
$-174.4M
Q2 25
$-6.0M
$-157.3M
Q1 25
$-2.0M
$-115.8M
Q4 24
$-4.1M
$-102.3M
Q3 24
$-4.2M
$-80.4M
Q2 24
$-3.2M
$-70.8M
Q1 24
$-1.7M
$-68.9M
Gross Margin
REED
REED
RNA
RNA
Q4 25
20.4%
Q3 25
17.4%
Q2 25
8.5%
Q1 25
33.9%
Q4 24
30.0%
Q3 24
18.0%
Q2 24
32.3%
Q1 24
35.6%
Operating Margin
REED
REED
RNA
RNA
Q4 25
-46.9%
Q3 25
-58.3%
-1513.5%
Q2 25
-60.8%
-4448.7%
Q1 25
-17.4%
-8360.9%
Q4 24
-37.6%
-4069.6%
Q3 24
-46.5%
-4200.9%
Q2 24
-5.6%
-4040.4%
Q1 24
-6.8%
-2178.6%
Net Margin
REED
REED
RNA
RNA
Q4 25
-50.5%
Q3 25
-56.6%
-1398.3%
Q2 25
-63.5%
-4089.3%
Q1 25
-20.3%
-7360.0%
Q4 24
-42.3%
-3439.5%
Q3 24
-61.5%
-3441.7%
Q2 24
-27.1%
-3461.8%
Q1 24
-17.4%
-1943.4%
EPS (diluted)
REED
REED
RNA
RNA
Q4 25
$-1.26
Q3 25
$-0.48
$-1.27
Q2 25
$-0.13
$-1.21
Q1 25
$-0.04
$-0.90
Q4 24
$-3.73
$-0.80
Q3 24
$-4.91
$-0.65
Q2 24
$-0.77
$-0.65
Q1 24
$-0.40
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
REED
REED
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$9.2M
$1.9B
Total Assets
$23.3M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
REED
REED
RNA
RNA
Q4 25
Q3 25
$350.2M
Q2 25
$243.9M
Q1 25
$254.2M
Q4 24
$219.9M
Q3 24
$370.2M
Q2 24
$575.8M
Q1 24
$471.4M
Stockholders' Equity
REED
REED
RNA
RNA
Q4 25
$9.2M
Q3 25
$2.8M
$1.9B
Q2 25
$1.7M
$1.2B
Q1 25
$4.7M
$1.3B
Q4 24
$6.6M
$1.4B
Q3 24
$-22.0M
$1.5B
Q2 24
$-23.8M
$1.2B
Q1 24
$-20.7M
$830.9M
Total Assets
REED
REED
RNA
RNA
Q4 25
$23.3M
Q3 25
$19.9M
$2.1B
Q2 25
$23.7M
$1.4B
Q1 25
$24.5M
$1.5B
Q4 24
$25.1M
$1.6B
Q3 24
$15.0M
$1.6B
Q2 24
$18.7M
$1.3B
Q1 24
$19.3M
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
REED
REED
RNA
RNA
Operating Cash FlowLast quarter
$-3.8M
$-156.2M
Free Cash FlowOCF − Capex
$-3.9M
$-156.9M
FCF MarginFCF / Revenue
-52.0%
-1257.6%
Capex IntensityCapex / Revenue
1.1%
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-17.3M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
REED
REED
RNA
RNA
Q4 25
$-3.8M
Q3 25
$-2.8M
$-156.2M
Q2 25
$-5.0M
$-199.7M
Q1 25
$-5.4M
$-124.8M
Q4 24
$-3.9M
$-99.9M
Q3 24
$1.1M
$-65.6M
Q2 24
$-912.0K
$-65.0M
Q1 24
$-2.4M
$-70.4M
Free Cash Flow
REED
REED
RNA
RNA
Q4 25
$-3.9M
Q3 25
$-2.9M
$-156.9M
Q2 25
$-5.1M
$-203.0M
Q1 25
$-5.4M
$-128.6M
Q4 24
$-4.0M
$-103.8M
Q3 24
$1.0M
$-67.3M
Q2 24
$-924.0K
$-65.5M
Q1 24
$-2.4M
$-71.3M
FCF Margin
REED
REED
RNA
RNA
Q4 25
-52.0%
Q3 25
-41.5%
-1257.6%
Q2 25
-53.2%
-5277.1%
Q1 25
-54.2%
-8174.3%
Q4 24
-40.8%
-3491.0%
Q3 24
15.3%
-2881.8%
Q2 24
-7.8%
-3204.6%
Q1 24
-25.1%
-2012.3%
Capex Intensity
REED
REED
RNA
RNA
Q4 25
1.1%
Q3 25
1.4%
5.7%
Q2 25
0.2%
86.9%
Q1 25
0.7%
238.6%
Q4 24
1.0%
131.7%
Q3 24
0.3%
72.9%
Q2 24
0.1%
26.0%
Q1 24
0.2%
25.8%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons